Drugs / Expanded Natural Killer (ENK) Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03003728 | Nov 2019 → Jul 2020 | plasma cell myeloma | University of Arkansas | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded Natural Killer (ENK) Cells | “Expanded Natural Killer (ENK) Cells” NCT03003728 ↗ |
| Action | Deplete | “have the ability to kill myeloma cells” NCT03003728 ↗ |
| Modality | Cell therapy | “natural killer cells will be collected and then treated in a laboratory to activate and 'expand' the number of cells to increase the dose and the anti-myeloma activity of the...” NCT03003728 ↗ |